^
    Back
    Association details:
    Biomarker:PTEN overexpression
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Ann Oncol
    Title:

    Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

    Excerpt:
    Subgroups of HNSCC patients who may achieve increased benefit from afatinib were identified based on prespecified tumor biomarkers (p16-negative, EGFR-amplified, HER3-low, PTEN-high).
    DOI:
    10.1093/annonc/mdx344
    Trial ID:
    LUX-Head&Neck 1
    Test:
    VeriStrat®
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).

    Published date:
    05/25/2023
    Excerpt:
    The UPSTREAM trial is a biomarker-driven umbrella trial of targeted therapies and immunotherapy for RM SCCHN (post-platinum, ECOG 0-1, measurable disease). The B1 cohort was a phase II, randomized, open-label substudy evaluating the efficacy of afatinib (orally, 40mg/day)....All responding patients had previously been treated with cetuximab, were PTEN high but none had EGFR or HER2 alterations.
    DOI:
    10.1200/JCO.2023.41.16_suppl.6034